With the introduction of INSUMAN®, a leading human Insulin product fromSanofi’s range of diabetes treatments, Sanofi is now one of the only companies that provides a full range of both oral and injectable treatments for patients with diabetes in Nigeria.
To better support the patients in the management of their disease, Sanofi has also announced their support in the opening of 12 dedicated diabetes and hypertension clinics in partnership with health authorities. The first Clinic was inaugurated recently at the Lagos State University Teaching Hospital.
In Nigeria, around 5 million people are suffering from diabetes and this figure is expected to double within the next 20 years, with 63% undiagnosed and many that are diagnosed, not correctly controlled. 76% of deaths due to diabetes are in people under the age of 60 on the African continent.
Patients are exposed to many complications including vascular complications, blindness and limb amputation, which can be prevented by treatment with Insulin and effective, close management of patients. With over 90 years’ experience in developing and manufacturing Insulin, Sanofi is a world leader in delivering quality, innovative solutions to meet the needs of patients.
The INSUMAN® range allows for individualized treatment (basal, rapid and premix) available in both Vials and Cartridges. The INSUMAN® cartridge uses a unique innovative technology that ensures a more accurate dosing. In Nigeria, it will be used with the award-winning ALLSTAR™ disposable pen for delivery.
According to Abderrahmane Chakibi (General Manager, Sanofi Nigeria-Ghana), “The introduction of INSUMAN® in combination with ALLSTAR™ in Nigeria demonstrates our commitment to patients, improving access and ensuring availability to high-quality, efficacious solutions to improve the management of diabetes for patients. INSUMAN® has been licensed in 90 countries and is manufactured in Germany to the highest international standards. Since its first introduction 17 years ago, more than 5 million patient-years with INSUMAN® have been accumulated. Combining the range with ALLSTAR™, a new, disposable, injection pen will help make the lives of patients easier in Nigeria with a simple, safe-to-use and affordable solution“.
Commenting on the support of the 12 new clinics in diabetes, he added “Delivering innovative treatments and a full portfolio adapted to the needs of patients locally is at the core of what we, at Sanofi, have done for nearly a century”.
“But medications alone are not enough. For many years, we have been supporting healthcare professionals in their daily practice through training and tailored services. In 2015, across Nigeria, we will support the creation of 12 clinics for Diabetes and Hypertension in partnership with health authorities. These clinics will be established in dedicated healthcare centers to increase screening, disease awareness and patient education. They will also provide better management and monitoring of people with diabetes though dedicated nursing and physician support. In 2016, we aim to deploy 24 more clinics” Chakibi concluded.
The availability of the new range of human insulin INSUMAN®, the injection pen ALLSTARTM and the support of clinics for the better management of the disease, is in direct response to the healthcare needs of patients with diabetes in Nigeria.